The rapid expansion of genomic medicine has intensified the need for scalable, regulatory-aligned and high-fidelity gene editing workflows that can efficiently transition from discovery to clinical evaluation. Aldevron and Integrated DNA Technologies (IDT) are at the forefront of a non-viral gene editing framework designed to support programs across in vivo and ex vivo therapeutic modalities. Emphasis is placed on editing specificity, off-target assessment and manufacturability to support IND-enabling studies. In this webinar, you will be able to:
- Map a non-viral CRISPR-mediated gene editing workflow to support in vivo and ex vivo genomic medicine applications.
- Understand manufacturability and quality constraints needed to ensure consistency, traceability and IND readiness for complex editing components.
- Integrate off target safety profiling, analytical services and regulatory expectations into an evidence package that supports non viral gene editing IND filings.